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I. Demand-driven innovation in healthcare 
 
The health market represents in most OECD countries around 10% of national gross 
domestic products (GDP), making Estonia one of the exceptions with a health market 
corresponding to around 6% of GDP. In addition contributes the public sector in most 
countries with 70-80 % of the spending in the health sector1. Public health authorities are 
therefore important actors in the innovation system, not only as adopters of health 
innovation taking place among suppliers but also potentially as “intelligent” public 
procurers formulating demand for innovative solutions. The BSHR HealthPort project 
focuses on the interactions between healthcare service providers and SMEs with the aim 
of enhancing innovation, reduce health care costs and promote Small and Medium-sized 
Enterprises’ (SMEs) access to the Baltic Sea Region healthcare market.  
 
Innovation emerges in general from interaction between suppliers, buyers and or other 
actors. As most healthcare service providers in the Baltic Sea Region are public 
organisations, this means that new products and services are developed many times as 
the result of interaction between public and private actors. There exists certain terms and 
notions that in different ways captures this interaction. One notion popularised in the 
Danish context is ‘public-private innovation’, which refers to different innovation generating 
interactions that may take place between a public agency and supplier(s) and/ or other 
organisations. To some extent it overlaps with the notion Public Innovation Partnerships 
understood as “a mutual cooperative arrangement between public and private 
organisations with the overall objective of innovating and developing public welfare 
solutions”2. Talking about public private innovation is useful as it emphasises the 
importance of interaction between the private sector and e.g. health authorities. The 
starting point in the analysis are many times suppliers’ potentially useful innovations, and 
the ambition to provide opportunities for interactive learning by giving suppliers access to 
e.g. hospital wards where new solutions can be tested. Even if such opportunities are 
useful for the development of innovative solutions, public private innovation projects have 
a tendency to remain in the pre-commercial stage. The actual procurement phase is 
typically not an integrated part of those projects. 
 
In the efforts to support public-private innovation of products and services in hospitals and 
the healthcare sector in general, a focus on the demand side is also important. This 
perspective emphasizes the role public agencies can play to formulate demand for 
supplier-side innovation, i.e. a complementary perspective to the public private innovation 
concept. Public demand-side innovation manifests in three main different ways;  
 
                                            
 
1
 OECD Health Data (2012). http://www.oecd.org/els/health-
systems/OECDHealthData2012FrequentlyRequestedData Accessed 16 April, 2013  
2
 Weihe G et al. (2011) Strategic use of public-private cooper-ation in the Nordic region. TemaNord, 
2011:510. Nordic Council of Ministers, Copenhagen. P. 14. 
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1. As public procurement projects, where e.g. a health authority sets up contracts for 
innovative solutions that requires some innovative effort from the supplier in order to meet 
the need defined.  
 
2. Long term signalling, expressed e.g. as long-term (master) plans outlining more 
strategic political ambitions formulated by a public authority. Examples seen are the goals 
set on different levels to become CO2 neutral within a defined deadline or the currently 
undergoing development in Denmark towards building a set of “super hospitals”. Even if 
these activities lack any formal incentives for suppliers in the way concrete tender calls do, 
these kinds of signals may affect firm’s strategic decisions on where to direct their 
innovation activities, to be able to meet public needs in the future.  
 
3. Standards and regulations, finally, may help both to remove depreciated and inefficient 
products from the market, but also induce innovation among firms currently not able to 
meet the standards and regulations. These pulling effects may be realised to the extent 
that the standards as well as regulations remain updated.  
 
The demand side perspective underscores the importance of that e.g. hospital managers 
and procurers, has to place demand for, procure and adopt new products and services 
widely for innovations to take effect. Dissemination of novel solutions in the healthcare 
sector hinges on them being procured and implemented in more than just isolated test 
sites, which is sometimes not an entirely problem-free task. Also, even if procurers are 
able to include an innovative product in a hospital’s electronic order-system, it may not be 
diffused and used within the organisation anyway. Organised scepticism among 
physicians, lack of technology champions, silo budgeting, problems related to establishing 
the value of the innovation, and issues concerning de-spending and already made contract 
commitments may inhibit or slow down adoption of innovation3. 
 
Associated with the demand-side is also the knowledge that prevails of the practice in 
which innovations are to be integrated. This knowledge prevails among health staff. Other 
interesting knowledge holders are patients and their next of kin. Given that this knowledge 
is utilised in procurement projects, the procurer may be thought of as an expert of the 
problem that needs to be solved, but not typically on the exact details of the solution. The 
supplier, on the other hand, may have in possession knowledge, skills and resources to 
come up with a solution, but lack specific knowledge about the specific need. The ultimate 
goal of the procurement process is in that sense to find a supplier that compensated with a 
certain amount of money will satisfy that need by applying its tools and skills to solve a 
particular problem. The knowledge prevailing in practice may work as sources of 
                                            
 
3 Rolfstam M., Phillips, W., Bakker, E. (2011). Public Procurement of Innovations, Diffusion and 
Endogenous Institutions. International Journal of Public Sector Management, Vol. 24 No. 5. Pp. 
452-468. 
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innovation, either by defining in rather open terms a problem that needs to be solved, or 
more specific suggestions on concrete devices that should be developed. Ultimately, the 
demand-side approach corresponds with the user-driven perspective of innovation which 
is a well-known mechanism leading to new solutions4. 
 
Finally, private companies are dependent on securing return of investments in innovation, 
i.e. they need to sell their products or services. In particular in the health-tech sector where 
public customers play such an important role, a well-functioning public demand-system is 
critical. This requires considerations regarding all phases from creating possibilities for 
testing working prototypes to actually selling a solution.  
 
Procurement by hospitals and doctors of products and services has traditionally been 
driven by economic considerations and for better patient treatment and care. Only 
recently, public procurement of healthcare solutions has been conceptualised as a means 
of driving regional economic development. Therefore, the conditions and possibilities of 
making that link is still investigated and experimented on. This paper contributes to these 
efforts by investigating framework conditions for public procurement of innovative solutions 
and recent developments in innovation policies and procurement practice in the Baltic Sea 
Region. 
 
The issue has in the course of this project been described in “BSHR Health Port Task Part 
2 of the State of The Region: Procurement as major source of boosting innovation in the 
region” by Christoffer Hermansson and Boo Edgar, where the importance of public 
procurement is stressed. This paper explores the identified barrier of the current 
procurement legislation. However, it should also be noted that many times are the legal 
issues per se not so problematic. Public procurement of innovation requires a range of 
skills, including legal skills, management skills and allocation of adequate resources. Of 
importance are also prevailing attitudes and norms. If a culture is natured that accepts 
public procurement as a too cumbersome process not useful for innovation, the chances 
for successful application is low. The interpretation of the meaning of the Directives may 
also play a role. Denmark for instance, appears in an international comparison as a 
country that applies a relatively strict interpretation of the rules. The successful application 
of public procurement as a means to stimulate innovation requires probably also therefore 
interventions aiming at developing a more innovation-friendly  interpretation of the rules, 
which includes also pinpointing already available possibilities within the existing legal 
framework. 
  
                                            
 
4
 von Hippel, E. (1976). The dominant role of users in the scientific instrument innovation process. Research 
Policy, 5, pp. 212-239. 
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II. Public procurement of innovative products and solutions 
 
 
In the European Union, the procurement of products and services by public authorities is 
regulated to ensure a fair and equal competition for private companies through two EU 
Directives on public procurement, the Utilities Directive 2004/17 and the Directive for the 
classic or public sector, Directive 2004/18. Other Directives that may apply are the 
2205/28 Directive that specifies principles and guidelines for good clinical practice for 
investigational products; or the 93/42 Directives concerning medical devices and the rules 
for CE-marking later amended in the 2007/47 Directive.  
 
In the following the regulation is described with a special view on procurement of 
innovative solutions5. 
 
Procurement of innovative solutions seen from the public sector. 
 
Public authorities must, in most situations follow detailed procedural rules when 
purchasing goods, services or construction works. The procedural rules are established to 
promote competition and ensure that public authorities buy the best and cheapest 
solutions. The rules of procedure arise from both national and EU legislation where the 
relationship between the two follows the subsidiarity principle. This means that all EU 
Member states should implement the Directives in national law. The EC procurement 
Directives apply when the price of the procured item exceeds certain threshold values. In 
addition to the rules provided in the EC Procurement Directives Member states may for 
instance regulate procurement under the threshold values. This means that the specific 
rules applied below the threshold values might vary between EU Member states.  
 
Procurement law in e.g. Denmark consists mainly of the Tender Act, which regulates the 
procurement of works, goods and services up to the so-called "threshold values", and 
above that the EU Public Procurement Directive and EU Utilities Directive. 
Procurement of goods and services may fall into one of four categories. If the value of the 
purchase exceeds the threshold, the Public Procurement Directive, procedural rules are 
followed. If the value is lower than the threshold, but above DKK 500.000 the Tender Act 
rules on advertising duty use, while procurement with a value lower than DKK 500.000 as 
a starting point is not governed by the Public Procurement Directive or Tender Act. Finally, 
the purchased service can be directly excluded Procurement Directive, and thus not 
subject to either supply or advertising requirement. In these cases it is not the value that 
determines which set of rules applies, but instead the subject of the purchase. 
 
Some types of purchases are more expensive to implement than others. This is important 
to be aware of when the purchase form is selected. Most costly for the public entity is the 
                                            
 
5
 Based on “Offentligt indkøb af innovation”, North Denmark Region, 2011. 
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pre-commercial procurement (PCP) procedure while traditional public tender is the least 
costly. Other forms like competitive dialogue range in between. 
 
The costs of procurement is however relative to the degree of complexity and uncertainty 
in the specific project. The application of more costly procedures such as the competitive 
dialogue may prove to be cheaper to use for the contracting authority than a traditional 
tender if the requirements specifications are very complicated to prepare. For instance, 
with competitive dialogue it is to some extent possible to allow contractors to contribute to 
the specification of requirements during the dialogue phase. This flexibility may help 
procurers to reach a more useful solution than would have been rendered with the 
application of the open procedure. Thus, although more costly, these “advanced” forms of 
procurement, may be better off to find a solution in an initially complex and uncertain 
situation. 
 
PCP will often be the most expensive procurement form due to the fact that several 
suppliers develop product/services in parallel, and that this development to some extent is 
paid by the public authority. On the other hand, several different ideas are tested, and the 
authority has a greater chance of getting the best innovative solution. In some cases, it 
may be possible to put much of the development cost on the suppliers, in which case the 
PCP is not going to cost more than other forms of procurement. PCP is more likely to 
provide innovative solutions than traditional tenders. The differences phases in PCP also 
reduces the risks for involved stakeholders, as suggested ideas that turns out to be less 
useful can be abandoned before the commercial procurement takes place. 
 
One of the biggest challenges in public private innovation projects as seen in Denmark 
concerns subsequent procurement of innovations emerging in development projects. One 
potential legal problem a contracting authority faces after development is that it might be 
difficult to buy on a commercial scale the product developed. If a contracting authority, for 
example, has an injection robot for use on the authority's hospitals developed, it is 
possible to buy a prototype and possibly also a small test series of this robot. A "test set" 
should not necessarily consist of a small number of copies, but may consist of the number 
of copies, which is necessary in order to ensure a sufficient quality of testing. However, if 
transparency and competition are maintained, procurement should be feasible. In order for 
the Authority to procure the robot on a commercial basis, a formal tender call needs to be 
published.   
 
The challenge of being able to make a subsequent commercial procurement is that the 
commercial procurement must be made in compliance with procurement rules, and that 
the object of the commercial procurement (the product to be developed) often is very 
difficult to describe at the time of purchase of the R & D performance. The supplier and the 
contracting authority must of course first through R & D efforts to develop the product to be 
procured. The usual solution to this problem is that several tender calls are issued, where 
each tender call represents different phases. One tender call could aim at procuring a 
feasibility study, another a pilot study, etc. Another technique seen is the application of 
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functional specification, i.e. what happens when the specification is based on the intended 
outcome or function, not the specific technical details of the solution. 
 
In a competition perspective, the particular challenge is to define the conditions under 
which the contracting authority subsequently wish to purchase the product developed, at 
the time of supply of R & D performance. These conditions include, among other things, 
the price, quantity and warranty obligations for the supplier. 
 
A possible solution of this problem may be - in advance - to develop pricing models based 
on the development costs plus a margin for the supplier. It is important here to note that 
such pricing models must be based on objectively verifiable assumptions, thus creating 
transparency on the value of the subsequent procurement. The possibility of developing 
such procurement models is facilitated to the extent that the contracting authority has the 
opportunity to engage in a dialogue with the suppliers or even to negotiate with suppliers 
on a price model. It is also possible for a procurer to state a maximum price that will paid. 
 
Often however, the contracting authority does not have prior knowledge of the work and 
the expenditure of the development work, while the interested suppliers will often have 
better conditions than the contracting authority to draft the required pricing models. 
For this reason, a wide range of R & D services and a subsequent procurement on a 
commercial scale, is often best be done using either a competitive dialogue or similar 
procedures. 
 
As far as the contracting authority's interest in being able to procure the product 
developed, this will often be dependent on the outcome of the development project. Can 
the product be used at all, or is the price is so high that the procurer does not want to buy 
the product? The purchasing authority will often have an interest in formulating this as an 
option, then the authority has the right but not the obligation, to buy a quantity of goods on 
the agreed terms, in some cases combined with a commitment to purchase a guaranteed 
amount. 
 
In the case of PCP, the Commission in its recommendations set out guidelines under 
which the procurer does not have the obligation or the right to purchase the solution or 
otherwise to let the developed product be part of the contract. The supplier must therefore 
still compete for any contract with the authority concerned to delivery of the developed 
solution. In the case of PCP, the Commission has not made final recommendations on the 
issue that the development of a single solution could result in a monopoly situation. The 
Commission sets out several options, where one of them is to have at least two suppliers 
complete the development of a solution so that authority is not bound, but has the option, 
to purchase from either developers. On the other hand should not a monopolistic situation 
out a problem, if the procurement is carried in compliance with the regulations. One 
Danish example is the procurement of the Patient Briefcase, a communication device that 
enables remote interaction between health staff and patients. The contract was given to 
the only supplier that could deliver the system, after the market was given a chance to 
object to this intention. 
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Another option is to give all suppliers the rights (IPR) of the developed solution. This may, 
e.g. be done by reserving the right to let other suppliers produce the solution, maybe 
conditioned by paying a license fee to the supplier, who participated in the development. 
Such an approach will in most cases be able to create competition for the contract, which 
(all else being equal) results in a lower price. However, the developer still has an 
advantage, since he did not have to pay licensing fees to produce the product, and to 
ensure open competition this must be addressed in the following tender. 
 
Six models of procurement in alignment with the Procurement Directive. 
 
Public procurement projects may be set up in different ways, applying different tender 
procedures as described in the Directives and different delivery forms. This section gives a 
brief presentation of the most common forms. The presentation provides an overview and 
an introduction to some of the key terms used. 
 
 
1. The default  tender procedure according to the Public Procurement Directives 
 
A public procurer can, according to the Procurement Directives, choose between two 
different types of tender procedures: the open and the restricted procedure. The open 
tender allows all interested suppliers to submit a bid, while the restricted procedure gives 
authority the possibility to select a limited number of suppliers to bid, typically based on a 
form of evaluation of qualifications. The latter is typically applied in contexts where the 
procurer wants to avoid the administration costs associated with handling unnecessarily 
many bids. Public procurement is typically performed using either the open or restricted 
procedure.  
 
At a open tender, the authority advertises in the electronic portal Tenders4 Electronic Daily 
(TED) that it wishes to make a purchase, and all potential suppliers are invited to submit a 
tender. The public authority must then send the tender conditions and any additional 
documents to anyone who requests it, or make information freely available, for example, 
the authority's website. The Authority must include a date for final bidding, and all tenders 
must be evaluated. The evaluation must be based on some already published award 
criteria that can be either "lowest price" or "most economically advantageous tender". The 
supplier that best meets the chosen award criteria must be awarded the contract. 
 
An open tender may result in many bids, which can make evaluation effort prohibitive. This 
can be avoided by using the method of restricted tendering procedure, which is divided 
into two phases. The first phase is called "pre-qualification" where suppliers can apply to 
tender, where typically their financial capacity and technical skills are presented. It is the 
authority that determines how the financial capacity and technical skills must be 
documented and evaluation in this phase relate only to determine candidates. The 
Authority will select objectively the best candidates who subsequently progress to the next 
stage and will be invited to tender (the "bidders"). The second phase is called the tender 
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phase and is identical to the process in a public offering with the exception that only the 
pre-qualified suppliers may submit a tender, and that the tenderers' qualifications are not 
evaluated again. 
 
 
2. Procurement of Research & Development Services without competition (Article 16f-
exception) 
 
The exemption of R&D service contracts from the Procurement Directive is used widely 
today in basic research. The exploitation, however, is not limited to basic research, but can 
be used for the purchase of all kinds of R & D benefits granted that the service has 
"research level". This means that there is effective research or development. An example 
of this might be the purchase of new product development, which can improve the 
Authority's service and does not exist on the market in advance. However, the 
development of new functionalities or interfaces to e.g. existing IT systems generally is not 
considered be an R & D performance. 
 
Since the procurement of R & D services are exempt from the Procurement Directive, such 
procurement is not following the complex procedural rules in the Procurement Directive or 
the general principles of EU law. A contract may be awarded directly to the desired 
partners without having to be sent out to tender. After having drawn up a contract with a 
partner, the development of the desired product is started. 
 
There is no requirement that the contract may not be changed continuously, and 
authorities can conduct a dialogue with the private partner throughout the development 
and change the product specifications along the way, as needs arise or change. If the R & 
D contract concerns development of a product (a commodity), the contracting authority 
also has the possibility of buying a prototype or a small test series of product directly from 
the developer / manufacturer through negotiation and without a public tender. A 
subsequent commercial supply of the developed product is not exempt from the 
Procurement Directive.  
 
An R & D contract can be referred to only cover the actual development of the product and 
possibly a prototype or some samples of the product to be used to test the functionality. 
After the functionality is demonstrated, and the product is ready for commercial production 
(mass production), the authority must use one of the other procurement forms for buying 
the product. 
 
If a research and/or development is 100% financed by the contracting authority, it is a 
requirement that all rights for development results (the so-called Intellectual Property 
Rights - abbreviated IPR) do not become the property of the contracting authority alone. 
This can be done by reporting results publicly, or by awarding the partner company the 
IPR in whole or in part. 
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3. Pre-commercial procurement (PCP) 
 
 
 
PCP is a method of procurement of research and development services, which is based 
on the above Article 16f-exception where the authority does not keep all rights to research 
results or the developed solution. The PCP method covers the Commission's 
recommendations and guidelines on how to implement the Article 16f-exemption to ensure 
that the authorities get the best possible research services. The PCP model also complies 
with the EU Treaty in the sense that it maintains competition throughout the process. 
 
PCP is different from the procurement of research and development services, as 
described above, primarily because the PCP focuses on competition and equal treatment 
in the selection of R & D partners, in the sense that the choice of partner is via tender and 
the award of the contract is based on objective, factual and non-discriminatory criteria. 
 
The PCP process involves more than one company on the supply side. Instead of working 
with one company several companies work in parallel development, ensuring competition, 
since the authority will be able to choose between different vendors' solutions / products 
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after development. Similarly, this process enhances the authority’s chances of developing 
a solution that meets its requirements when several different solutions are developed. 
 
Since it is very costly to have more than one company to develop a solution – typically 
paid by the contracting authority – PCP operates as a starting point with a continuous 
selection of suppliers. The process is divided into phases, as determined by the public 
authority. At the end of each phase the authority evaluate the solutions and choose which 
suppliers can proceed to the next phase. In this manner, the continued development 
involves only the most promising solutions. The Commission recommends that the 
contracting authority, if possible, leave at least two companies carry out the whole process 
by which the public authority does not end up being tied to a single vendor solution in a 
subsequent procurement. 
 
As described, PCP is mainly suited for development projects with a high social and 
economic value, where gains are comparable with the cost of development for both the 
contracting authority and the participating suppliers. 
 
Rights to development results (IPR) must not become the property of the public authority 
alone, but must be shared with the private company developing the solution. In practice, 
this means that the company can then sell the newly developed product to other 
customers for commercial purposes. 
 
 
4. Procurement of innovative solutions through framework agreements 
 
A framework agreement is an agreement setting out the terms of future contracts between 
one or more authorities and one or more suppliers. Subsequent agreements are made on 
the basis of the terms set out in the framework agreement, as long as it runs. 
 
It is only the framework agreement that need to be offered under the ordinary rules of 
procurement. The following contracts awarded under the framework agreement will not 
have to go through a tendering process again. The Authority can in this way make a single 
agreement instead of having to award contracts, each time the specified product or service 
is procured. 
 
Services to be procured on the basis of a framework agreement need not be precisely 
described. It may, e.g. be sufficient to describe the services as "Engineering consultancy in 
hospital refurbishing". 
 
In a framework agreement for innovative services, these services therefore need not be 
described down to the smallest detail. This gives the authority greater freedom to modify 
the requirements during the period of the framework agreement, and may even use the 
same supplier to develop solutions for various demands. 
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Framework agreements for consultancy services can in this way for example be suitable 
for procurement of R & D services in areas where over a period multiple projects are 
expected to start, and where the individual projects at the time of tendering is not yet fully 
defined. 
 
If the authority concludes parallel framework agreements with several suppliers, the 
individual contracts under framework agreements must be awarded by predetermined 
conditions or as a result of so-called "mini-tender" where competition is reopened, e.g. for 
the price for the specific task. 
 
 
5. The Design contest 
 
The  design contest is a procedure, where the authority wishes to give participants 
(suppliers) great freedom to develop an innovative solution. The procedure used in 
particular for spatial planning, urban planning, architectural and engineering work and new 
development of IT systems, but can also be used where the task calls for innovation, idea 
generation and creativity. 
 
In practice, the procedure has most importance in architectural competitions. 
The main idea behind the contest is that one of several submitted solutions will be 
selected by a jury. The evaluation of the solutions must be in accordance with 
predetermined award criteria and composition of the jury must reflect the academic 
requirements for participants in the contest. 
 
The design contest can be implemented as an open or restricted tender, and the 
procedure allows, without additional tender or advertising, to sign a contract with the 
winner of the competition for the purchase of the solution. When signing the contract for 
the purchase of the solution, the authority also has the possibility to procure an 
implementation of the solution (for example, an IT system) without tendering, as long as 
there is a direct functional relationship with the developed solution. If the purchase of the 
solution also requires the procurement of goods (e.g. hardware), it is possible without 
further tendering if the value of the services exceeds the value of the goods. It is also 
possible to set up a design competition as the initial procurement project, followed by a 
tender call aiming at realising the proposed design. 
 
 
6. The Competitive dialogue 
 
The competitive dialogue is a procedure, which was introduced in response to many 
authorities’ wish to expand dialogue with bidders in order to find the optimal solution. 
 
Actual negotiation is still not allowed, but with the competitive dialogue it is possible for the 
authorities to conduct a dialogue with the candidates on legal, economic or technical 
aspects of the purchase. Dialogue is conducted prior to final submission, after which the 
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authority is precluded from further dialogue / negotiation with bidders. Competitive 
dialogue should be used only in the case of particularly complex contracts, but are often 
very useful in relation to the purchase of innovative solutions. By "particularly complex 
contracts" means that the authority can not specify in detail the desired technical solution 
or that the legal and/or financial conditions applicable to the contract cannot be specified. 
 
The contracting authority can thus draw upon the participating suppliers' experience and 
expertise to specify the requirements for the desired solution, makes tender form 
particularly suitable for procurement of innovation. The requirements cannot be changed 
after the contract is signed, but the competitive dialogue is still considerably more flexible 
than the open and restricted procedures as the authority has significantly better chance of 
describing the solution adequately. 
 
 
Public Procurement of innovation 
 
Public procurement of innovation has been defined as as “purchasing activities carried out 
by public agencies that lead to innovation”6. From the above descriptions it follows that 
there are no single format for procuring healthcare innovation. It depends on the actual 
situation e.g. the size of the contract, the complexity of the solution and the expected level 
of innovation. Generally, innovative solutions can be developed and procured when a fair 
and equal competition is ensured. Especially, the IPR of a given solution cannot be the 
sole property of the public authority, and the private part must not get any competitive 
advantage by engaging in the innovation project. 
 
Innovation cooperation between public and private entities has been present in healthcare 
for long, but has been accentuated in the recent decades. The relationship is 
characterized by the partners being engaged in a co-creation process towards solutions to 
common defined problems. Therefore, it is not a traditional procurement of known 
solutions, nor a cooperation partnership focused more on effective operations rather that 
development of innovation and knowledge sharing. 
 
A tentative and general model of procurement of innovative solutions and technology can 
be constructed as: 
 
I. Pre-procurement process: 
Prior to a tender there is a process of preparing that includes among other 
considerations: exploration of need, budgetary considerations, defining of tender 
criteria, preparations of procurement process etc. 
 
II. Procurement process: 
                                            
 
6
 E.g. Rolfstam, M. 2012. An Institutional Approach to Research on Public Procurement of Innovation. 
Innovation The European Journal of Social Science Research. 25 (3), pp. 303-321.  
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The procurement process itself contains steps like formulating a tender, 
conducting the procurement and selecting a provider. 
 
III. Post-procurement process: 
Establish cooperation between provider and procurer, negotiating contract 
specifics, et cetera. And, in some instances, engage in post-sale services 
agreements. 
 
In each process, innovative elements can be developed within the legal boundaries.  
E.g. in the pre-procurement process, research and development activities can be 
employed to investigate the future envisioned practice and user perspectives, as well as 
creating a business case for subsequent procurement. 
 
During the procurement phase, some of the models described earlier can be employed, 
e.g. the model for pre-commercial procurement. 
 
Finally, during the post-procurement process, a window of innovation can be exploited by 
securing cooperation and synergy between provider and procurer – within the conditions of 
the tender. For product innovation, diffusion of the procured innovation within the 
organisation may be an important component. 
 
Obviously, the room for innovation is higher earlier in the overall process, and the different 
innovation drivers can more easily be exploited in the early process. Insights from 
research may provide novel products and systems, and special emphasis on user needs 
and alignment with existing systems and frameworks may provide a basis for effects 
during implementation. 
 
Procurement practice 
 
Given the complexity of the regulation of procurement of innovative solutions, the actual 
practice of procuring vary in the different countries and institutions. 
 
A trend in the Nordic countries over the last 30 years has pointed towards a change, 
where healthcare professionals increasingly accept that productivity/efficiency are term 
that are legitimate in healthcare systems 7.  
 
To some extent professional administrators have permeated the hospitals in the same 
period, and introduced business logics, e.g. in procurement practice8. 
 
In a recent study (Simon-Kucher), the change in procurement practice is described as: 
 
                                            
 
7
 Lehto, J. et.al. 2012. The Impact of Macro-economic Crises on Nordic Health Systems Policies, European 
Health Policy Group. 
8
 “Sundhedsvæsen, sundhedsteknologi og medico”, Fremkom, NDR, 2012 
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 Increasing power of purchasing departments as well as an increasing degree of 
purchasing centralization. 
 Centralized procurement is largely associated with decreasing price levels, a 
reduced innovation adoption and supplier lockout.9 
 
The centralization of healthcare procurement is expected to decrease the adoption of 
innovative solutions by focusing on price and scale. Centralized procurement may also 
reduce the possibilities to utilize knowledge and needs identified by health staff and 
patients. 
 
Sometimes claims are made concerning the administrative burden associated with bidding 
on public tenders, and that the bureaucracy should inhibit public procurement of innovation 
projects. This is especially important for SMEs as they are heavily burdened by such pre-
procurement costs. It is obviously necessary to take into account these kinds of 
complaints. The general claim that the law inhibits innovation remains however 
unsupported in research. If one actually looks at why public procurement of innovation 
goes wrong, or fails entirely, the reasons found prevail typically on other levels than formal 
law. Less successful attempts to procure innovation can many times be explained by poor 
management, lack of legal competence, lack of the resources required to conduct public 
procurement of innovation projects. Sometimes the reasons for the negative perceptions 
can be found in poor training and awareness, both among suppliers as well as public 
procurers. What needs to be taken into account is also that the public procurement rules 
play an important role to prevent fraud, maintain competition and thereby lower the prices 
public procurers have to pay. Public procurement is a commercial activity aiming at finding 
the most economically advantageous bid. This means also, like in any business situation, 
companies must learn to loose.  
 
There is a need for public politics to actively support innovation efforts, and the 
establishing of a new partnership between public authorities and private companies, 
especially SMEs. There are several ways of doing this and to some extent the issue 
becomes one about diffusion information about these options rather than try to develop 
anything which is not already applied. Public procurers may to larger extent than what is 
done today unbundle projects, and allow bids from consortia. They may also allow 
submissions addressing subsets of elements specified in a tender call. One should also 
take into account that SMEs may also participate in public procurement of innovation as 
sub-suppliers to large companies. This is very common in the construction sector. Even if 
the contract with the procuring agency is typically held by a large contractor, it is 
dependent on an array of sub-contractors to deliver the procured solution. By engaging in 
such projects, SME’s would be able to focus on its core activities, while project 
management and administration would be carried by the large company. For some SMEs, 
in particular start-ups within pharmacological sector, the intention might even be never to 
reach the market themselves. Instead, when a certain maturity stage has been reached, it 
                                            
 
9
 ” Centralized Public Procurement, Decision Makers, Tenders and Innovation”, Simon-Kucher, Stuttgart, 
2012. 
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expects to be bought up by a multinational company that in turn will manage the 
commercialisation stage. 
 
In the following section, recent developments in the Baltic Sea Region are summarised to 
illustrate how public policy answers the need for innovation support. 
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III. Regional differences in policies and practice of public 
innovation and procurement 
 
 
In the following a status on innovation policies in seven of the region’s countries is 
summarized, with a special focus on healthcare innovation10. 
 
 
Lithuania: 
 
Innovative public procurement. In 2009, the Law on Public Procurement in Lithuania 
implemented provisions of EC Public Procurement directives allowing contracting 
authorities to procure innovative products, services or works through competitive dialogue 
procedure; to describe wanted product through functional specification, desired 
performance; to offer possibility of alternative proposals, preliminary contracts, thus, 
supporting innovation through public procurement (as mentioned in the Innotrend Country 
Report Lithuania, 2009). In the LIS Action Plan for 2007-2013 the Ministry of Economy 
sets an objective to promote the adoption of innovative procurement. First it intends to 
carry out a feasibility study during 2011-2013 on the adoption of innovative procurement 
practices in Lithuania, based on the experience of other countries 
 
So far, the Lithuanian innovation policy has focused on the supply-side and has paid little 
attention to the demand-side for innovation. Nevertheless, there are weak signs of the 
emerging awareness on the demand-side policies. 
 
According to Pro-Inno Europe there are no new demand-side innovation policy measures 
introduced since 2009. The discussion on the introduction of such measures is only 
starting to emerge at the policy design level in Lithuania. Moreover, this debate only 
concerns ‘soft’ measures – like awareness raising – not fully realising the potential of 
demand-side policies. 
 
Denmark: 
 
In the Danish policy debate the concept of public procurement has not been used as much 
as in the European context. In Denmark concepts like public-private innovation and public-
private partnership are more commonly used. 
 
Recently Denmark has implemented policy initiatives related to public procurement of 
innovations related to new hospitals and refurnishing of old hospitals. Furthermore, 
procurement of innovative solutions has been stated by the government as a means of 
growth. 
 
                                            
 
10
 Based on Mini Country Reports from Pro-Inno Europe. 
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Estonia: 
 
The innovation system in Estonia was mainly set up in the beginning of 2000’s when not 
only the legislation and institutions related to R&D and innovation but the whole public 
functional system was built up and made functioning. 
 
The idea of e-health and electronic health record already emerged in 2002. The purpose 
was to develop a nationwide framework (database) to facilitate the exchange of digital 
medical documents and diffuse health information available so far only in local databases 
and information systems that were not able to communicate with each other. E-health 
gathers all patients’ information in one database, doctors send digi-prescriptions directly to 
the pharmacy via e-health database and patients can have the medicine in any pharmacy 
all over Estonia. 
 
There is a new measures launched since 2009: “National programme for health and R&D: 
sub-programme: Development of capacity of Health Science 2010-2015”, which aims to 
develop Estonian healthcare sector. 
 
Estonian innovation policy framework has remained unchanged since 2007 and does not 
include any public demand-side measure. So far, the demand-side measures have not 
been under discussion neither there are no ideas what could be possible demand-side 
measures. There are recent developments in e-services initiated by the Government, as 
examples of demand-side innovation as there are nothing alternative to present. 
 
Finland: 
 
The role of public sector as a customer is also emphasized, especially in the development 
of demand and user driven innovations. However, in general the main role of the public 
sector is seen to be in ensuring existence of a well-functioning, fair and competitive 
marketplace for the companies to operate on. 
 
The Framework and Action Plan for Demand and User-driven Innovation Policy14 was 
published in 2010 by the Ministry of Employment and the Economy. 
The action plan running through the years 2010 - 2013 covers the action points that 
promote policy implementation in the private and public sectors.  
 
The Ministry of Employment and the Economy is implementing the action plan in 
cooperation with several other ministries and a broad range of stakeholders, such as 
Tekes, VTT, the National Consumer Research Centre and Forum Virium Helsinki11 .The 
Action Plan identifies several policy priorities for innovation policy activities to support 
demand-side innovation between 2010 and 2013.  
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 Ministry of Employment and the Economy 15/2011 
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These include: 
• Promoting innovation friendly regulation; 
• Development of standardisation to provide more effective support to innovation; 
• Promoting the emergence of lead markets; 
• Development of funding models for the introduction of investment-intensive innovations. 
 
Germany: 
 
Germany has strong focus on early interaction between potential users of new 
technology and those actors that develop technology. Public procurement has 
received increasing attention, though there is an ongoing debate over the effectiveness 
of the state as a lead user. 
 
Demand-side innovation policy in Germany received a new stimulus by the High-tech 
Strategy 2020 of the German Government presented in 2010. One area is health and 
nutrition. 
 
Also, the BioPharma programme is a particularly interesting activity from a demand-side 
policy view. Started in 2007, its main goal is to link different actors like researchers, 
hospitals, biotechnology and pharmaceutical companies, agencies and health insurances 
along the supply chain in order to develop and commercialise new biopharmaceuticals. 
Co-operation between the different partners is expected to lead to strategic optimisation, 
accelerated innovation processes and less failure of new biopharmaceuticals in approval 
and market introduction stages. 
 
Public procurement is another important element of demand-side innovation policy in 
Germany. An important step was an amendment to the Law against Restraints on 
Competition that now allows public authorities to impose additional demands on 
contractors to foster innovative solutions. 
 
In the German policy debate, public procurement is sometimes seen rather sceptical as an 
effective tool for stimulating innovation. First, innovations should stand the test in the 
market, particularly in international markets. Secondly, public procurement needs to follow 
strict cost-efficiency rules which limit the possibility of public entities to demand innovations 
that are more expensive than standard products and cannot clearly prove superior 
performance. 
 
Latvia: 
 
In 2006, the Parliament of Latvia passed new Public Procurement Law. The Law relates to 
the procurement made by state or municipal institutions, and to companies fully or partly 
owned or financed by such institutions. The law is an implementation of the EU Public 
Procurement Directive, and Latvia is therefore aligned with the European regulation.  
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Latvia does not pursue a demand-side innovation policy, and at present, to our knowledge 
no study or training is taking place in the field of innovation procurement. There is 
information on some special procurement used for innovation in Latvia, but those are not 
public measures and are used by a particular company or institute for its own needs. 
 
Nevertheless, a national research program is under implementation with the aim to create 
new personalised medical technologies and treatment, and means for the improvement of 
public health. 
 
 
Poland: 
 
The origins of the public innovation policies, especially public procurement of innovation 
date back to April 2008, when a jointly prepared document on New approaches to public 
procurement by the Ministry of Economy in cooperation with the Public Procurement Office 
was adopted by the Council of Minister. 
 
With regard to SMEs and public procurement, the document formulated a series of 
recommendations which were around the aspects of undertaking the assessments of 
barriers hampering access of the SMEs to public procurement, facilitating the access to 
advisory services and trainings, development of the Public Procurement Office portal, and 
ensure the provision of information about the public procurement in the existing business 
intermediary organisations. Similar type of recommendations were put forward as regards 
the role of public procurement in support of innovation activities (Ministry of Economy, 
2008). 
 
Recently, the Public Procurement Office has prepared a number of guides on public 
procurement, e.g. Public procurement conducive to innovation. 
 
Whilst in general there are no specific lead-market type of initiatives, the programmes and 
project supported by the National R&D Centre (NCBiR) are the closest to the 
characteristics of this type of support instruments because the Centre is tasked to manage 
and implement strategic scientific research and development programmes, that translate 
directly into innovation development. 
 
The use of public procurement as a tool in supporting innovation is limited. The situation 
has been slowly changing and certainly a strategic project commissioned by the Polish 
Agency for Enterprises Development (PARP) plays an important role, because it is 
precisely a programme to step up the knowledge, but also raise awareness of existing 
possibilities to use new approaches to public procurement more effectively. 
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IV. Entrepreneurial activities 
 
This section examines the entrepreneurial activities associated with healthcare 
innovations, and construct a model for categorising different processes for entrepreneurs. 
The results builds partly on the survey data derived in the BSHR HealthPort WP3 on 
“Regional capabilities and existing practices survey”, 2012. The data from the survey 
points towards the importance of the entrepreneurs’ organisation, commercialisation 
initiatives, and adoption of innovations for future growth. 
 
In the following the entrepreneurial activities are described in three sections: demand or 
procurement of products, business development and support structures. Also, three 
archetypical start-ups are used to illustrate different characteristics and conditions 
regarding product and development process. 
 
 
Demand and procurement 
 
Most entrepreneurs in healthcare are potential suppliers for the public healthcare sector, 
which poses a range of obstacles. 
 
For pharmaceutical start-ups the innovation is typically based on research, and the 
process from theoretical and laboratory results to clinical evidence is long. The link 
between research results and clinical needs is therefore to a large extent uncertain. 
 
For medico-technical start-ups the sales horizon is not as long, and the need for clinical 
insight is therefore higher. The medico-technical companies are typically more reliant on a 
direct interaction with clinicians, and have a strong focus on providing value for doctors 
and hospital administrators. 
 
For ICT based start-ups, the envelope is even faster, and typical customer is not the public 
healthcare provider in the first place. Rather the healthcare start-up focuses on the 
consumer market or joins with an established healthcare solution provider. 
 
Especially companies with a short time-to-market seem to have a more conservative 
approach to collaboration with the customers and view their relationship as mainly sale. 
For start-ups with a longer time-to-market the relationship with potential customers are 
more often characterised as innovation collaboration. 
 
 
Business Development 
 
Start-ups in the healthcare area seem to follow entrepreneurs in other fields with regards 
to business development. This need for business skills in the management team is 
apparently a general trait in all of the three types of start-ups. Apart from the cases where 
business competencies were present from the initial construction of the company or added 
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early in the development phase, the entrepreneurs were more driven by functionality and 
technical aspect of the start-up. 
 
The hypothesis that research-based entrepreneurs would be underrepresented with 
business skills were not found, perhaps due to the capital demands in most 
pharmaceutical companies and the following need for including business competencies. 
 
 
Support structures 
 
The survey found that collaboration with support structures such as incubators were 
common.  
 
Also, enrolment in entrepreneurship programmes is generally used by start-ups in the 
healthcare sector. 
 
The distribution, however, seem to vary between the three groups of start-ups. 
 
The group of companies with a strong focus on research and a long time-to-market are 
seen to be more integrated in incubators – especially connected to universities. 
 
The groups oriented towards medico technical products generally move quicker into 
business centres or establish own production sites, and drawn on a broader variety of 
business support like experts in e.g. logistics, IPR, human resource etc. 
 
The group characterised by mainly being software developers are seldom seen in 
incubators closely related to universities, and do not draw on experts in the same degree 
as medico technical companies. Rather, the ICT oriented start-ups are oriented towards 
the marketing aspects and collaboration with other software start-ups, e.g. in business 
centres. 
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A process map of entrepreneurs 
 
 
The characteristic needs for the entrepreneurs are summed up in the table below. 
 
 Pharma and 
research-based 
start-ups 
Medico technical 
start-ups 
ICT oriented start-
ups 
Demand and 
Procurement 
Creation of needs in 
procuring 
organisations 
Collaboration with 
professionals and 
decision makers. 
Marketing and 
partnering with 
solution providers. 
Business 
Development 
Business skills, 
especially financing. 
Business skills, 
especially project 
management. 
Business skills, 
especially in 
marketing and 
partnering. 
Support structures Typically close 
connected with 
universities or 
research 
organisations. 
Diverse field of 
expert advice, and 
access to production 
and test facilities. 
Professional 
sparring and access 
to sales channels. 
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V. Final remarks 
 
This report has focussed on public procurement of innovative products and services in the 
healthcare sector. 
 
It has shown that there is an increasing ambition for seeking synergy between innovation 
in healthcare and regional economic development. 
 
The formal conditions for public procurement (above the threshold values) are regulated 
throughout the European Union by the national implementations of the Procurement 
Directive. 
 
The regulations provides for innovative measures before procurement, e.g. regarding 
research on technical innovations and user needs. Models of procurement, e.g. “pre-
commercial procurement” can be employed to increase the innovation level during the 
procurement phase. 
 
Some countries in the Baltic Sea Region have adopted strategies to utilise the healthcare 
expenditure to support development of the private sector, but few have succeeded in 
creating publicly driven programmes or initiatives where the innovative level of public 
procurement has provided the expected effects. 
 
The study points towards a number of recommendations to support public procurement of 
healthcare innovations. 
 
Both public and private actors need to be more competent in designing procurement 
processes and providing corresponding offers, where focus is on supplying effective 
healthcare solutions within the legal framework. 
 
For entrepreneurs, different approaches to support and development must be employed as 
the field of start-ups in the healthcare sector is very diverse. 
 
Supporting public actions to increase innovation in the different procurement processes 
are needed to fully exploit the innovative potentials, especially in the pre-procurement 
process. 
 
Across the Baltic Sea Region there appears to be a wide spread of focus and experience 
regarding public support policies and initiatives. This leads to a need for harmonising 
procurement practises and models before the Baltic Sea Region healthcare market can 
become a common innovation platform in the healthcare sector. 
 
 
 
